(TSE) A pulse sequence characterized by a series of rapidly applied 180° rephasing pulses and multiple echoes.

See Fast spin echo.

(TFE) Turbo field echo is a gradient echo pulse sequence with data acquisition after an initial 180° (similar to IR) preparation pulse for contrast enhancement. The difference between a FFE and TFE other than the speed of the sequence is that the image is acquired while approaching steady state (the echoes are collected during the time in which the tissues are experiencing T1 relaxation).
The contrast is prepared one time, which means the contrast is changing while the echoes are collected and can be manipulated by selecting the type and timing of the prepulse. A delay time is given before the actual image acquisition. To achieve T1 contrast the 180° prepulse is followed by an operator selected delay time, that results in no signal from the targeted tissue. So when the echoes are acquired, no signal is present, additional RF spoiling is performed to optimize for T1 contrast. The delay chosen corresponds to when T1 relaxation reaches and suppresses T1 signal or optimizes the difference between tissues. Contrast for these sequences are enhanced when K-space is filled using a centric or low-high ordering. A TFE can be acquired with a 2D or 3D technique and with or without T1, T2 weighting.
See Ultrafast Gradient Echo Sequence, TurboFLASH and Magnetization Prepared Rapid Gradient Echo (MPRAGE).

(BWA) A flexible surface coil for body imaging.

See Carr Purcell Meiboom Gill sequence.

(McAb) Monoclonal antibodies are used for tumor detection and localization in nuclear medicine. In MRI, monoclonal antibodies labeled with paramagnetic or superparamagnetic particles are being studied for targeting tumors, for example contrast agent containing gadolinium attached to a targeting antibody. The antibody would bind to a specific target (e.g., a metastatic melanoma cell) while the gadolinium would increase the MRI signal. Further developments are MRI contrast agents that specifically target glucose receptors on tumor cells; coupled with the high spatial resolution of high field MRI devices, these agents have potentials to detect small tumor foci.
The monoclonal antibody manufacturers produce a wide variety of ligands, which can be directed against a multiplicity of pathologic molecular targets. MRI enhanced with targeted contrast agents can be used for molecular imaging.